Tue. Jul 23rd, 2024

Tohoku University’s research team has created a latest and more effective cancer therapy

The Graduate School of Biomedical Engineering at Tohoku University has created a lymphatic drug delivery system (LDDS) that allows anticancer medications to be administered directly into metastatic LNs.

Rapid therapy is essential because lymph node (LN) metastases in cancer patients is an indication that things are becoming worse.

A research team from Tohoku University’s Graduate School of Biomedical Engineering has developed a lymphatic drug delivery system (LDDS), where anticancer drugs are injected directly into the metastatic LNs. When combined with total-body irradiation (TBI), the new LDDS has a superior antitumor effect than conventional chemotherapy on early-stage LN metastasis.

TBI provides a uniform dose of radiation to the entire body, penetrating areas in traditional chemotherapy cannot reach. Recently, TBI has shown positive results in activating immune responses and altering the tumor microenvironment. Meanwhile, LDDS is mainly used for treating metastatic LNs locally.

The research team hoped to widen LDDS’s usage to prevent distant metastases where the cancer spreads from the primary tumor to a distant lymph node.

“We knew a combination of treatment that enhances systemic tumor immune effects would be an important therapeutic strategy,” said graduate student Shota Sora, who was part of the research team headed by Professor Tetsuya Kodama.

Sora and his colleagues investigated the dual therapy of LDDS and TBI on metastasis model mice for LN and distant metastases. They used irradiation gamma rays (a one-time dose of 1.0 GY) and anticancer drug CDDP adjusted with a solvent to have an osmotic pressure of 1987 kPa and a viscosity of 11.3 mPas.

An in vivo bioluminescence imaging system, a high frequency ultrasound system, and histology showed the new therapy was more effective than employing LDDS or TBI alone. After the therapy, the expression of immune-response related genes (CD4, CD8, and IL-12b) increased in the spleen, indicating an activated immune response.

“With the results showing that both TBI and LDDS improve the efficacy of LB metastasis and distant metastases therapy, this novel approach is a promising way to treat cancer patients,” added Sora.

By Editor

Related Post

Social media & sharing icons powered by UltimatelySocial

Enjoy this blog? Please spread the word :)